1999
DOI: 10.1016/s0014-2999(99)00084-9
|View full text |Cite
|
Sign up to set email alerts
|

Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

8
38
1

Year Published

2000
2000
2015
2015

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 43 publications
(48 citation statements)
references
References 24 publications
8
38
1
Order By: Relevance
“…Taken together, GBR 12909 induced only minor changes in dopamine metabolism and there were no indications of potentiation by COMT deficiency on these effects. These results fit quite well with previous findings in rats, where GBR 12909 alone had no effect on DOPAC and HVA striatal extracellular and brain tissue concentrations (Westerink et al, 1987;Irifune et al, 1995;Budygin et al, 1999;Huotari et al, 1999). However, when tolcapone, a selective and potent COMT inhibitor (Borgulya et al, 1989), was given together with 20 mg/kg GBR 12909, striatal extracellular DOPAC levels were slightly increased (Huotari et al, 1999), whereas with 10 mg/kg GBR 12909 DOPAC levels remained unaltered (Budygin et al, 1999).…”
Section: Discussionsupporting
confidence: 91%
See 1 more Smart Citation
“…Taken together, GBR 12909 induced only minor changes in dopamine metabolism and there were no indications of potentiation by COMT deficiency on these effects. These results fit quite well with previous findings in rats, where GBR 12909 alone had no effect on DOPAC and HVA striatal extracellular and brain tissue concentrations (Westerink et al, 1987;Irifune et al, 1995;Budygin et al, 1999;Huotari et al, 1999). However, when tolcapone, a selective and potent COMT inhibitor (Borgulya et al, 1989), was given together with 20 mg/kg GBR 12909, striatal extracellular DOPAC levels were slightly increased (Huotari et al, 1999), whereas with 10 mg/kg GBR 12909 DOPAC levels remained unaltered (Budygin et al, 1999).…”
Section: Discussionsupporting
confidence: 91%
“…In previous studies with rats, the selective COMT inhibitor tolcapone was able, to some extent, to potentiate GBR 12909-induced elevation of striatal extracellular dopamine concentration (Budygin et al, 1999;Huotari et al, 1999). In the present study, we have investigated the effects of the dopamine uptake inhibition on locomotor activity, the levels of catecholamines and their metabolites in three different brain regions, and dopamine concentration in striatal extracellular fluid of COMT-deficient mice of both sexes.…”
mentioning
confidence: 83%
“…Our present neurochemical results in COMT-deficient mice with a lower dose (2.5 mg/kg) of d-amphetamine are in line with previous findings that COMT inhibition did not further potentiate d-amphetamine-induced changes in neurochemical or behavioral parameters Tuomainen et al 1996). This contrasts with the results of similar experiments with low doses of GBR 12909, a pure DAT inhibitor (Andersen 1989), where the effects of the drug on dopamine levels were augmented by both a potent COMT inhibitor tolcapone (Budygin et al 1999;Huotari et al 1999) and the lack of COMT (Huotari et al 2002b).…”
Section: Discussionsupporting
confidence: 88%
“…Properly spaced in time, the dopamine release from a mild stimulation train (e.g., bipolar, 24 pulses, 60 Hz, 120 A) is highly reproducible, with minimal effects on behavior. Therefore, electrically evoked dopamine release and uptake can be monitored before and after administration of a drug (1,(51)(52)(53)(54). Background-subtracted cyclic voltammograms in a freely moving male rat (solid lines) were matched to a template of electrically evoked dopamine release in the same rat (dashed lines).…”
Section: Electrically Stimulated Dopamine Releasementioning
confidence: 99%